Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Connection

Search Results to Rohit Dhall

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Dhall, Rohit

PropertyValue
keywords Parkinson's Disease
overview My clinical expertise in diagnosis and management of Neurodegenerative disorders, including parkinsonism, dementias, dystonia and tremor. My clinical research focuses on developing novel diagnostics and therapeutics, and improving programs delivering care to neurological patients. I direct the division of Neurodegenerative Disorders, and UAMS' Parkinson Foundation Comprehensive Care Center, and CurePSP Center of Care, and co-direct the Huntington Disease Center of Excellence. I also serve as the Medical Director of the Clinical Trials Innovation Unit at the Translational Research Institute at UAMS.

One or more keywords matched the following items that are connected to Dhall, Rohit

Item TypeName
Concept Huntington Disease
Concept Alzheimer Disease
Concept Parkinson Disease
Concept Metabolic Diseases
Concept Disease Progression
Concept Lung Diseases
Academic Article National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers.
Academic Article Parkinson's disease severity and use of dopaminergic medications.
Academic Article Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
Academic Article Sex Differences in Clinical Features of Early, Treated Parkinson's Disease.
Academic Article A mobile cloud-based Parkinson's disease assessment system for home-based monitoring.
Academic Article No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.
Academic Article Advances in levodopa therapy for Parkinson disease: Review of RYTARY (carbidopa and levodopa) clinical efficacy and safety.
Academic Article Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
Academic Article Finger displacement in Parkinson disease: up? down? sideways?
Academic Article Parkinson's disease outcomes after intraoperative CT-guided "asleep" deep brain stimulation in the globus pallidus internus.
Academic Article Distinguishing the tremor of Parkinson's disease from essential tremor: finger displacement.
Academic Article A simple question about falls to distinguish balance and gait difficulties in Parkinson's disease.
Academic Article Longer Duration of MAO-B Inhibitor Exposure is Associated with Less Clinical Decline in Parkinson's Disease: An?Analysis?of?NET-PD LS1.
Academic Article Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.
Academic Article Awake versus asleep deep brain stimulation for Parkinson's disease: a critical comparison and meta-analysis.
Academic Article Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial.
Academic Article National randomized controlled trial of virtual house calls for Parkinson disease.
Academic Article Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1.
Academic Article Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease.
Academic Article Downward finger displacement distinguishes Parkinson disease dementia from Alzheimer disease.
Academic Article Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores.
Academic Article Clinical outcomes following awake and asleep deep brain stimulation for Parkinson disease.
Academic Article Dosing Patterns during Conversion to IPX066, Extended-Release Carbidopa-Levodopa (ER CD-LD), in Parkinson's Disease with Motor Fluctuations.
Academic Article Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson's Clinic.
Grant A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa- Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off”
Grant A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects with Advanced Parkinson’s Disease 205998
Grant a Phase 2, double-blind, randomized, placebo-controlled study of nelotanserin versus placebo in patients with dementia with Lewy bodies (DLB) and Parkingson's Disease Dementia (PDD) who have REM Sleep behavior disorder (RBD)
Academic Article Inhaled levodopa in Parkinson's disease patients with OFF periods: A randomized 12-month pulmonary safety study.
Academic Article Coordinated Reset Vibrotactile Stimulation Induces Sustained Cumulative Benefits in Parkinson's Disease.
Academic Article Olfactory Deficits in the Freezing of Gait Phenotype of Parkinson's Disease.
Academic Article Clinical Efficacy and Dosing of Vibrotactile Coordinated Reset Stimulation in Motor and Non-motor Symptoms of Parkinson's Disease: A Study Protocol.
Grant a Phase 2, double-blind, randomized, placebo-controlled study of nelotanserin versus placebo in patients with dementia with Lewy bodies (DLB) and Parkingson's Disease Dementia (PDD) who have REM Sleep behavior disorder (RBD)
Academic Article Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Academic Article The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Academic Article A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
Grant A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (IRB 274673)
Grant 58 Week Open-label Trial of Tavapadon in Parkinson's Disease (TemPO-4 Trial) (IRB 262509)
Grant A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants with Early Parkinson's Disease (IRB 274317)
Grant Development of the Virtual Unified Huntington Disease Rating Scale (vUHDRS™) (IRB 274554)
Grant A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)
Grant A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects with Early Parkinson's Disease (IRB 273929)
Grant A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (IRB 274673)
Grant A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects with Early Parkinson's Disease (IRB 273929)
Grant 58 Week Open-label Trial of Tavapadon in Parkinson's Disease (TemPO-4 Trial) (IRB 262509)
Academic Article Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Academic Article Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.

Search Criteria
  • Disease